SCHEMBL16636010

SCHEMBL16636010

Cc1nc(C2CCC(F)CC2C(=O)O)cs1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.38
GPR88 Q9GZN0 1/20 0.36
ALDH1A1 P00352 2/20 0.36
RAB9A P51151 4/20 0.34
NPC1 O15118 3/20 0.34
KDM4E B2RXH2 1/20 0.34
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34
HTT P42858 1/20 0.34
PDE9A O76083 2/20 0.34
ECE1 P42892 2/20 0.33
MAPT P10636 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
DPP4 P27487 1/20 0.32
DPP8 Q6V1X1 1/20 0.32
DPP9 Q86TI2 1/20 0.32
MAPK1 P28482 1/20 0.32
KDM4A O75164 1/20 0.32
KDM4B O94953 1/20 0.32
KDM5C P41229 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16636518 0.86 NPC1 (0.35) FFAR1GPR88ALDH1A1RAB9ANPC1
SCHEMBL16636519 0.86 NPC1 (0.35) FFAR1GPR88ALDH1A1RAB9ANPC1
SCHEMBL16635938 0.75 EIF4E (0.35) FFAR1
SCHEMBL16636348 0.74 PIM1 (0.37) FFAR1KDM4ESMN1; SMN2
SCHEMBL16636278 0.72 L3MBTL1 (0.30)
SCHEMBL17158887 0.70 NR4A2 (0.36) FFAR1GPR88ALDH1A1RAB9APOLB
SCHEMBL17158885 0.70 NR4A2 (0.36) FFAR1GPR88ALDH1A1RAB9APOLB
SCHEMBL16636099 0.69 SLC6A2 (0.45) ALDH1A1RAB9ANPC1KDM4EECE1
SCHEMBL2583252 0.68 ADORA1 (0.46) ALDH1A1RAB9ANPC1KDM4EPOLB
SCHEMBL22492047 0.67 FFAR1 (0.49) FFAR1ALDH1A1KDM4EMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
WO-2015051479-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ FFAR1 4283/4885GPR88 2941/4885ALDH1A1 4582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.